DOCSLIB.ORG

TRAF5, a Novel Tumor Necrosis Factor Receptor-Associated Factor Family

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TRAF5, a Novel Tumor Necrosis Factor Receptor-Associated Factor Family Proc. Natl. Acad. Sci. USA Vol. 93, pp. 9437-9442, September 1996 Biochemistry TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling (signal transduction/protein-protein interaction/yeast two-hybrid system) TAKAoMI ISHIDA*, TADASHI ToJo*, TSUTOMU AOKI*, NORIHIKO KOBAYASHI*, TSUKASA OHISHI*, TOSHIKI WATANABEt, TADASHI YAMAMOTO*, AND JUN-ICHIRO INOUE*t Departments of *Oncology and tPathology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan Communicated by David Baltimore, Massachusetts Institute of Technology, Cambridge, MA, May 22, 1996 (received for review March 8, 1996) ABSTRACT Signals emanating from CD40 play crucial called a death domain, suggesting that these receptors could roles in B-cell function. To identify molecules that transduce have either common or similar signaling mechanisms (13). CD40 signalings, we have used the yeast two-hybrid system to Biochemical purification of receptor-associated proteins or the clone cDNAs encoding proteins that bind the cytoplasmic tail recently developed cDNA cloning system that uses yeast of CD40. A cDNA encoding a putative signal transducer genetic selection led to the discovery of two groups of signal protein, designated TRAF5, has been molecularly cloned. transducer molecules. Members of the first group are proteins TRAF5 has a tumor necrosis factor receptor-associated factor with a TRAF domain for TNFR2 and CD40 such as TRAF1, (TRAF) domain in its carboxyl terminus and is most homol- TRAF2 (17), and TRAF3, also known as CD40bp, LAP-1, or ogous to TRAF3, also known as CRAF1, CD40bp, or LAP-1, CRAF1 or CD40 receptor-associated factor (18-20). Those of a previously identified CD40-associated factor. The amino second group are proteins with a death domain for FAS and terminus has a RING finger domain, a cluster of zinc fingers TNFR1 such as FADD (21), also known as MORT1 (22), RIP and a coiled-coil domain, which are also present in other (23), and TRADD (24). members of the TRAF family protein except for TRAF1. In CD40 signalings were reported to include modulation of the vitro binding assays revealed that TRAF5 associates with the activity of nonreceptor-type tyrosine kinases such as Lyn, Fyn, cytoplasmic tail of CD40, but not with the cytoplasmic tail of and Syk, activation of phosphatidylinositol-3-kinase, phos- tumor receptor factor receptor type 2, which associates with phorylation of phospholipase C-y2 (25-27), activation of the TRAF2. Based on analysis of the association between TRAF5 Rel/nuclear factorKB (NFKB) transcription factors (28), and and various CD40 mutants, residues 230-269 of CD40 are induction of the Bcl-XL, Cdk4, and Cdk6 proteins (29). It has required for the association with TRAF5. In contrast to also been shown that tyrosine kinase activity is essential for TRAF3, overexpression of TRAF5 activates transcription factor CD40-mediated rescue of the germinal center B cells from nuclear factor #cB. Furthermore, amino-terminally truncated apoptosis (30). Among these signals, the Rel/NFKB activation forms ofTRAF5 suppress the CD40-mediated induction ofCD23 was shown to be mediated by TRAF2 (31). Although it was expression, as is the case with TRAF. These results suggest that demonstrated that all three known TRAF proteins can be TRAF5 and TRAF3 could be involved in both common and recruited to the cytoplasmic domain of CD40, the precise distinct signaling pathways emanating from CD40. mechanism by which CD40 mediates diverse signals remains to be elucidated. To characterize the initial stage of signaling by CD40, we have used the yeast two-hybrid system to identify CD40 is expressed in late B cells in bone marrow, mature B cDNAs encoding a novel protein containing a TRAF domain, cells, and certain accessory cells, including bone-marrow de- TRAF5, which is closely related to TRAF3 (18-20). We also rived dendritic cells and follicular dendritic cells (1-3), and is show that TRAF5 is involved in CD40 signaling linked to a receptor for CD40 ligand (CD40L) present on activated NFKB activation and CD23 expression. CD4+ T cells (4). Signaling through CD40 rescues B cells from apoptosis induced by crosslinking of the surface immunoglob- MATERIALS AND METHODS ulin M (IgM) complex (5) and also induces B cells to differ- Yeast Two-Hybrid System. DNA encoding the intracellular entiate and to undergo Ig isotype switching (6, 7). CD40L has domain of mouse CD40 (amino acids 216-306) was cloned into been shown to be defective in patients with X-linked hyper IgM the yeast LexA DNA-binding domain vector pBTM116. The syndrome, whose B cells do not form germinal centers and resulting plasmid, pBTM40cyt, was used as bait in two-hybrid produce only IgM and/or IgD (8). In addition, their B cells screens of a murine C57 Black Kaplan cDNA library fused to have the ability to switch from IgM to IgG, IgE, or IgA the activation domain of Gal4 in the pACT plasmid (CLON- production in vitro by the stimulation of CD40 (9). This genetic TECH). Seventy-two of the 2 x 106 transformants screened evidence strongly supports the idea that the intercellular grew in the absence of histidine and had detectable f3-galac- communication through CD40-CD40L is essential for germi- tosidase staining within 20 min of incubation. To remove nal center formation and Ig class switching. clones containing either TRAF3 or TRAF2, plasmids ex- CD40 is a member of the tumor necrosis factor receptor tracted from each yeast colony were subjected to Southern (TNFR) superfamily, which includes TNFR1 and TNFR2 (10, blotting probed with TRAF3 and TRAF2 cDNA. Ten clones, 11), lymphotoxin 13 receptor (12), Fas antigen (13), OX40 (14), which were not hybridized with either of two probes, were used CD30 (15), and the low-affinity nerve growth factor receptor (16), all of which share a ligand-binding domain composed of Abbreviations: TRAF, tumor necrosis factor receptor-associated fac- tandemly repeated cysteine-rich modules. Among these, Fas tor; NFKB, nuclear factor KB; CD40L, CD40 ligand; IgM, immuno- antigen and TNFR1 have significant similarity in their cyto- globulin M; TNFR, tumor necrosis factor receptor; GST, glutathione plasmic domain over 46 amino acids, a part of the domain S-transferase; CAT, chloramphenicol acetyltransferase. Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. D83528). The publication costs of this article were defrayed in part by page charge ITo whom reprint requests should be addressed at: Department of payment. This article must therefore be hereby marked "advertisement" in Oncology, The Institute of Medical Science, The University ofTokyo, accordance with 18 U.S.C. §1734 solely to indicate this fact. 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan. 9437 Downloaded by guest on September 28, 2021 9438 Biochemistry: Ishida et al. Proc. Natl. Acad. Sci. USA 93 (1996) in a cotransformation assay with pBTM40cyt or control pBT- CD23 Expression Assay. Mouse WEHI-231 B-cell clones MLamin bait to reconfirm the specificity. Then these clones expressing the FLAG-C40-3 protein were generated by intro- were subjected to nucleotide sequencing. ducing pME-FLAG-C40-3 together with an expression vector cDNA Cloning and Northern Blotting. The cDNA insert of for the puromycin resistant gene (pApuro) followed by selec- approximately 1 kbp from two-hybrid clone C40-3 was used as tion in the presence of 0.5 ,ug/ml of puromycin (38). For a probe to screen mouse testis cDNA library in AZAPII controls, cells were transfected with pApuro alone and sub- (Stratagene, provided by M. Ohsugi) by standard methods. jected to selection. More than 10 clones were isolated and Two independent positive clones were obtained and subjected expression of FLAG-C40-3 was checked by Western blotting. to nucleotide sequencing by the BcaBest sequence system Every clone was confirmed to express normal levels of mouse (Takara Shuzo, Shiga). The total RNA from various tissue was CD40. WEHI-231 cell clones with or without expression of prepared as described (32). The purification of poly(A)+ RNA FLAG-C40-3 were stimulated with mouse CD40L-CD8 chi- was performed using oligo(dT) latex (Takara Shuzo). Seven meric protein (39) for 48 hr. For controls, medium was added micrograms of poly(A)+ RNA was separated by 1% formal- instead of stimulator. After stimulation, cells were stained with dehyde denaturing agarose gel and transferred to nylon mem- fluorescein isothiocyanate-conjugated anti-CD23 antibody brane (Hybond N, Amersham). The filter was incubated with followed by FACScan analysis using the Lysis II program. Side 32P-labeled C40-3 cDNA probe in hybridization buffer [0.2 M scatter values were also measured to confirm that the charac- NaHPO4, pH 7.2/1 mM EDTA/1% (wt/vol) BSA/7% (wt/vol) terization of cells was not dramatically changed during the SDS] at 65°C. The filter was finally washed with 0.5 x drug selection process. SSC/0.2% (wt/vol) SDS at 65°C for 30 min. Glutathione S-Transferase (GST) Fusion Protein and the RESULTS Binding Assay. Plasmids encoding CD40 mutants with Thr-254 Structure and Expression of TRAF5. From 2 x 106 clones to Ala-254 substitutions, carboxyl-terminal truncation, or in- of a murine C57 Black Kaplan T-cell lymphoma cDNA library, ternal deletion were generated by the method of Kunkel (33). 10 independent clones were isolated that met all specific DNA fragments encoding cytoplasmic tail of CD40 and its criteria for binding to the cytoplasmic tail of CD40 in yeast. mutants were subcloned into the GST fusion protein vector Nucleotide sequencing of all cDNA fragments revealed that pGEX2T (Pharmacia LKB) and transformed into the Esche- three (clones C40-3, C40-6, and C40-72) encoded portions of richia coli strain BL21.
Load more

Recommended publications
  • Targeting Tgfβ Signal Transduction for Cancer Therapy
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Targeting TGFβ signal transduction for cancer therapy Sijia Liu1, Jiang Ren1 and Peter ten Dijke1 Transforming growth factor-β (TGFβ) family members are structurally and functionally related cytokines that have diverse effects on the regulation of cell fate during embryonic development and in the maintenance of adult tissue homeostasis. Dysregulation of TGFβ family signaling can lead to a plethora of developmental disorders and diseases, including cancer, immune dysfunction, and fibrosis. In this review, we focus on TGFβ, a well-characterized family member that has a dichotomous role in cancer progression, acting in early stages as a tumor suppressor and in late stages as a tumor promoter. The functions of TGFβ are not limited to the regulation of proliferation, differentiation, apoptosis, epithelial–mesenchymal transition, and metastasis of cancer cells. Recent reports have related TGFβ to effects on cells that are present in the tumor microenvironment through the stimulation of extracellular matrix deposition, promotion of angiogenesis, and suppression of the anti-tumor immune reaction. The pro-oncogenic roles of TGFβ have attracted considerable attention because their intervention provides a therapeutic approach for cancer patients. However, the critical function of TGFβ in maintaining tissue homeostasis makes targeting TGFβ a challenge. Here, we review the pleiotropic functions of TGFβ in cancer initiation and progression, summarize the recent clinical advancements regarding TGFβ signaling interventions for cancer treatment, and discuss the remaining challenges and opportunities related to targeting this pathway. We provide a perspective on synergistic therapies that combine anti-TGFβ therapy with cytotoxic chemotherapy, targeted therapy, radiotherapy, or immunotherapy.
    [Show full text]
  • A TRAF2 Binding Independent Region of TNFR2 Is Responsible for TRAF2 Depletion and Enhancement of Cytotoxicity Driven by TNFR1
    www.impactjournals.com/oncotarget/ Oncotarget, January, Vol. 5, No. 1 A TRAF2 binding independent region of TNFR2 is responsible for TRAF2 depletion and enhancement of cytotoxicity driven by TNFR1 Lucía Cabal-Hierro1,3, Noelia Artime1, Julián Iglesias1, Miguel A. Prado1,4, Lorea Ugarte-Gil1, Pedro Casado1,5, Belén Fernández-García1, Bryant G. Darnay2 and Pedro S. Lazo1. 1 Departamento de Bioquímica y Biología Molecular and Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain. 2 University of Texas. MD Anderson Cancer Center. Houston, Texas, USA. 3 Present address: Abramson Cancer Center. Perelman School of Medicine, University of Pennsylvania Philadelphia, PA. USA. 4 Present address: Department of Cell Biology. Harvard Medical School. Boston, MA. USA. 5 Present address: Institute of Cancer, Barts Cancer Institute. Queen Mary University of London. London, UK Correspondence to: Pedro S. Lazo, email:[email protected] Keywords: TNF receptors; Death Receptors; TRAF2; Apoptosis; NF-kappaB Received: October 11, 2013 Accepted: November 27, 2013 Published: November 29, 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Tumor Necrosis Factor (TNF) interacts with two receptors known as TNFR1 and TNFR2. TNFR1 activation may result in either cell proliferation or cell death. TNFR2 activates Nuclear Factor-kappaB (NF-kB) and c-Jun N-terminal kinase (JNK) which lead to transcriptional activation of genes related to cell proliferation and survival. This depends on the binding of TNF Receptor Associated Factor 2 (TRAF2) to the receptor.
    [Show full text]
  • Mechanism of Action Through an IFN Type I-Independent Responses To
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 is online at: average * The Journal of Immunology , 12 of which you can access for free at: 2012; 188:3088-3098; Prepublished online 20 from submission to initial decision 4 weeks from acceptance to publication February 2012; doi: 10.4049/jimmunol.1101764 http://www.jimmunol.org/content/188/7/3088 MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action Elena Caproni, Elaine Tritto, Mario Cortese, Alessandro Muzzi, Flaviana Mosca, Elisabetta Monaci, Barbara Baudner, Anja Seubert and Ennio De Gregorio J Immunol cites 33 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/02/21/jimmunol.110176 4.DC1 This article http://www.jimmunol.org/content/188/7/3088.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767
    [Show full text]
  • Expression of the Tumor Necrosis Factor Receptor-Associated Factors
    Expression of the Tumor Necrosis Factor Receptor- Associated Factors (TRAFs) 1 and 2 is a Characteristic Feature of Hodgkin and Reed-Sternberg Cells Keith F. Izban, M.D., Melek Ergin, M.D, Robert L. Martinez, B.A., HT(ASCP), Serhan Alkan, M.D. Department of Pathology, Loyola University Medical Center, Maywood, Illinois the HD cell lines. Although KMH2 showed weak Tumor necrosis factor receptor–associated factors expression, the remaining HD cell lines also lacked (TRAFs) are a recently established group of proteins TRAF5 protein. These data demonstrate that consti- involved in the intracellular signal transduction of tutive expression of TRAF1 and TRAF2 is a charac- several members of the tumor necrosis factor recep- teristic feature of HRS cells from both patient and tor (TNFR) superfamily. Recently, specific members cell line specimens. Furthermore, with the excep- of the TRAF family have been implicated in promot- tion of TRAF1 expression, HRS cells from the three ing cell survival as well as activation of the tran- HD cell lines showed similar TRAF protein expres- ␬ scription factor NF- B. We investigated the consti- sion patterns. Overall, these findings demonstrate tutive expression of TRAF1 and TRAF2 in Hodgkin the expression of several TRAF proteins in HD. Sig- and Reed–Sternberg (HRS) cells from archived nificantly, the altered regulation of selective TRAF paraffin-embedded tissues obtained from 21 pa- proteins may reflect HRS cell response to stimula- tients diagnosed with classical Hodgkin’s disease tion from the microenvironment and potentially (HD). In a selective portion of cases, examination of contribute both to apoptosis resistance and cell HRS cells for Epstein-Barr virus (EBV)–encoded maintenance of HRS cells.
    [Show full text]
  • TRAF5, a Novel Tumor Necrosis Factor Receptor-Associated Factor Family
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 9437-9442, September 1996 Biochemistry TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling (signal transduction/protein-protein interaction/yeast two-hybrid system) TAKAoMI ISHIDA*, TADASHI ToJo*, TSUTOMU AOKI*, NORIHIKO KOBAYASHI*, TSUKASA OHISHI*, TOSHIKI WATANABEt, TADASHI YAMAMOTO*, AND JUN-ICHIRO INOUE*t Departments of *Oncology and tPathology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan Communicated by David Baltimore, Massachusetts Institute of Technology, Cambridge, MA, May 22, 1996 (received for review March 8, 1996) ABSTRACT Signals emanating from CD40 play crucial called a death domain, suggesting that these receptors could roles in B-cell function. To identify molecules that transduce have either common or similar signaling mechanisms (13). CD40 signalings, we have used the yeast two-hybrid system to Biochemical purification of receptor-associated proteins or the clone cDNAs encoding proteins that bind the cytoplasmic tail recently developed cDNA cloning system that uses yeast of CD40. A cDNA encoding a putative signal transducer genetic selection led to the discovery of two groups of signal protein, designated TRAF5, has been molecularly cloned. transducer molecules. Members of the first group are proteins TRAF5 has a tumor necrosis factor receptor-associated factor with a TRAF domain for TNFR2 and CD40 such as TRAF1, (TRAF) domain in its carboxyl terminus and is most homol- TRAF2 (17), and TRAF3, also known as CD40bp, LAP-1, or ogous to TRAF3, also known as CRAF1, CD40bp, or LAP-1, CRAF1 or CD40 receptor-associated factor (18-20).
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]
  • Nuclear TRAF3 Is a Negative Regulator of CREB in B Cells
    Nuclear TRAF3 is a negative regulator of CREB in B cells Nurbek Mambetsarieva,b,c,1, Wai W. Linb,1, Laura L. Stunza,d, Brett M. Hansona, Joanne M. Hildebranda,2, and Gail A. Bishopa,b,d,e,f,3 aDepartment of Microbiology, University of Iowa, Iowa City, IA 52242; bImmunology Graduate Program, University of Iowa, Iowa City, IA 52242; cMedical Scientist Training Program, University of Iowa, Iowa City, IA 52242; dHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242; eInternal Medicine, University of Iowa, Iowa City, IA 52242; and fDepartment of Veterans Affairs Medical Center, Research (151), Iowa City, IA 52246 Edited by Louis M. Staudt, National Cancer Institute, NIH, Bethesda, MD, and approved December 14, 2015 (received for review July 23, 2015) The adaptor protein TNF receptor-associated factor 3 (TRAF3) regu- deficient T cells and macrophages lack the enhanced survival phe- lates signaling through B-lymphocyte receptors, including CD40, notype, although they display constitutive NF-κB2 activation (12, BAFF receptor, and Toll-like receptors, and also plays a critical role 13). TRAF3 degradation is neither necessary nor sufficient for B-cell inhibiting B-cell homoeostatic survival. Consistent withthesefindings, NF-κB2 activation (14). These findings indicate that TRAF3 regu- loss-of-function human TRAF3 mutations are common in B-cell cancers, lates additional important prosurvival pathways in B cells. particularly multiple myeloma and B-cell lymphoma. B cells of B-cell– Nuclear localization of TRAF3 has been reported in several specific TRAF3−/− mice (B-Traf3−/−) display remarkably enhanced sur- nonhematopoietic cell types (15, 16), but the function of TRAF3 vival compared with littermate control (WT) B cells.
    [Show full text]
  • Crystallographic Analysis of CD40 Recognition and Signaling by Human TRAF2
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 8408–8413, July 1999 Biochemistry Crystallographic analysis of CD40 recognition and signaling by human TRAF2 SARAH M. MCWHIRTER*, STEVEN S. PULLEN†,JAMES M. HOLTON*, JAMES J. CRUTE†,MARILYN R. KEHRY†, AND TOM ALBER*‡ *Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720-3206, and †Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368 Communicated by Peter S. Kim, Massachusetts Institute of Technology, Cambridge, MA, May 26, 1999 (received for review April 25, 1999) ABSTRACT Tumor necrosis factor receptor superfamily proteins (8, 9). The biological selectivity of signaling also relies members convey signals that promote diverse cellular re- on the oligomerization specificity and receptor affinity of the sponses. Receptor trimerization by extracellular ligands ini- TRAFs. tiates signaling by recruiting members of the tumor necrosis The TNF receptor superfamily member, CD40, mediates factor receptor-associated factor (TRAF) family of adapter diverse responses. In antigen-presenting cells that constitu- proteins to the receptor cytoplasmic domains. We report the tively express CD40, it plays a critical role in T cell-dependent 2.4-Å crystal structure of a 22-kDa, receptor-binding fragment immune responses (10). TRAF1, TRAF2, TRAF3, and of TRAF2 complexed with a functionally defined peptide from TRAF6 binding sites in the 62-aa, CD40 cytoplasmic domain the cytoplasmic domain of the CD40 receptor. TRAF2 forms have been mapped (7, 11). TRAF1, TRAF2, and TRAF3 bind a mushroom-shaped trimer consisting of a coiled coil and a to the same sequence, 250PVQET, and TRAF6 binds to the unique ␤-sandwich domain. Both domains mediate trimer- membrane-proximal sequence, 231QEPQEINF.
    [Show full text]
  • Cell Type-Specific Function of TRAF2 and TRAF3 in Regulating Type I IFN
    Xie et al. Cell Biosci (2019) 9:5 https://doi.org/10.1186/s13578-018-0268-5 Cell & Bioscience RESEARCH Open Access Cell type‑specifc function of TRAF2 and TRAF3 in regulating type I IFN induction Xiaoping Xie1, Jin Jin2, Lele Zhu1, Zuliang Jie1, Yanchuan Li1, Baoyu Zhao3, Xuhong Cheng1, Pingwei Li3 and Shao‑Cong Sun1,4* Abstract Background: TRAF3 is known as a central mediator of type I interferon (IFN) induction by various pattern recognition receptors, but the in vivo function of TRAF3 in host defense against viral infection is poorly defned due to the lack of a viable mouse model. Results: Here we show that mice carrying conditional deletion of TRAF3 in myeloid cells or dendritic cells do not have a signifcant defect in host defense against vesicular stomatitis virus (VSV) infection. However, whole-body inducible deletion of TRAF3 renders mice more sensitive to VSV infection. Consistently, TRAF3 was essential for type I IFN induction in mouse embryonic fbroblasts (MEFs) but not in macrophages. In dendritic cells, TRAF3 was required for type I IFN induction by TLR ligands but not by viruses. We further show that the IFN-regulating function is not unique to TRAF3, since TRAF2 is an essential mediator of type I IFN induction in several cell types, including mac‑ rophages, DCs, and MEFs. Conclusions: These fndings suggest that both TRAF2 and TRAF3 play a crucial role in type I IFN induction, but their functions are cell type- and stimulus-specifc. Keywords: TRAF2, TRAF3, Type I interferon, Antiviral immunity Background IPS-1) serves as an adaptor of RLRs, whereas stimulator Type I interferon (IFN) plays a crucial role in innate of interferon gene (STING) mediates type I IFN induc- immunity against viral infections [1, 2].
    [Show full text]
  • Lipid Rafts Are Important for the Association of RANK and TRAF6
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 35, No. 4, 279-284, August 2003 Lipid rafts are important for the association of RANK and TRAF6 Hyunil Ha1,3, Han Bok Kwak1,2,3, Introduction Soo Woong Lee1,2,3, Hong-Hee Kim2,4, 1,2,3,5 Osteoclasts are multinucleated giant cells responsible and Zang Hee Lee for bone resorption. These cells are differentiated from 1 hematopoietic myeloid precursors of the monocyte/ National Research Laboratory for Bone Metabolism macrophage lineage (Suda et al., 1992). For the dif- 2Research Center for Proteineous Materials 3 ferentiation of osteoclast precursors into mature osteo- School of Dentistry clasts, a cell-to-cell interaction between osteoclast Chosun University, Gwangju 501-759, Korea 4 precursors and osteoblasts/stromal cells are required Department of Cell and Developmental Biology (Udagawa et al., 1990). Recently, many studies have College of Dentistry, Seoul National University provided ample evidences that the TNF family mem- Seoul 110-749, Korea κ 5 ber RANKL (receptor activator of NF- B ligand; also Corresponding author: Tel, 82-62-230-6872; known as ODF, OPGL, and TRANCE) is expressed Fax, 82-62-227-6589; E-mail, [email protected] on the surface of osteoblasts/stromal cells and es- sential for osteoclast differentiation (Anderson et al., Accepted 19 June 2003 1997; Yasuda et al., 1998; Takahashi et al., 1999). When its receptor RANK was stimulated by RANKL, Abbreviations: MAPK, mitogen-activated protein kinase; MCD, several TNF receptor-associated factors (TRAFs), methyl-β-cyclodextrin; RANK, receptor activator of NF-κB; TLR, especially TRAF6, can be directly recruited into RANK Toll-like receptor; TNFR, TNF receptor; TRAF, TNF receptor- cytoplasmic domains and may trigger downstream associated factor signaling molecules for the activation of NF-κB and mitogen activated protein kinases (MAPKs) (Darnay et al., 1998; Wong et al., 1998; Kim et al., 1999).
    [Show full text]
  • TRAF6, a Molecular Bridge Spanning Adaptive Immunity, Innate Immunity and Osteoimmunology Hao Wu1* and Joseph R
    Review articles TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology Hao Wu1* and Joseph R. Arron2 Summary receptor/Toll-like receptor (IL-1R/TLR) superfamily. Gene Tumor necrosis factor (TNF) receptor associated factor targeting experiments have identified several indispen- 6 (TRAF6) is a crucial signaling molecule regulating a sable physiological functions of TRAF6, and structural diverse array of physiological processes, including and biochemical studies have revealed the potential adaptive immunity, innate immunity, bone metabolism mechanisms of its action. By virtue of its many signaling and the development of several tissues including lymph roles, TRAF6 represents an important target in the regu- nodes, mammary glands, skin and the central nervous lation of many disease processes, including immunity, system. It is a member of a group of six closely related inflammation and osteoporosis. BioEssays 25:1096– TRAF proteins, which serve as adapter molecules, coupl- 1105, 2003. ß 2003 Wiley Periodicals, Inc. ing the TNF receptor (TNFR) superfamily to intracellular signaling events. Among the TRAF proteins, TRAF6 is unique in that, in addition to mediating TNFR family Introduction signaling, it is also essential for signaling downstream of The tumor necrosis factor (TNF) receptor associated factors an unrelated family of receptors, the interleukin-1 (IL-1) (TRAFs) were first identified as two intracellular proteins, TRAF1 and TRAF2, associated with TNF-R2,(1) a member of 1Department of Biochemistry, Weill Medical College of Cornell the TNF receptor (TNFR) superfamily. There are currently six University, New York. mammalian TRAFs (TRAF1-6), which have emerged as 2Tri-Institutional MD-PhD Program, Weill Medical College of Cornell important proximal signal transducers for the TNFR super- University, New York.
    [Show full text]
  • Receptor Activator of NF-UB Recruits Multiple TRAF Family Adaptors and Activates C-Jun N-Terminal Kinase
    FEBS 21470 FEBS Letters 443 (1999) 297^302 Receptor activator of NF-UB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase Hong-Hee Kima, Da Eun Leea, Jin Na Shina, Yong Soo Leea, Yoo Mi Jeona, Chae-Heon Chunga, Jian Nib, Byoung Se Kwonc, Zang Hee Leea;* aDepartment of Microbiology and Immunology, Chosun University Dental School, 375 Seosuk-Dong, Dong-Ku, Kwangju 501-759, South Korea bHuman Genome Sciences, Inc., Rockville, MD 20850, USA cDepartment of Life Sciences, Ulsan University, Ulsan, South Korea Received 7 December 1998 trabecular bone and lower in spleen and bone marrow [3], Abstract Receptor activator of NF-UB (RANK) is a recently cloned member of the tumor necrosis factor receptor (TNFR) which suggests physiological functions of RANK in the regu- superfamily, and its function has been implicated in osteoclast lation of bone and immune systems. Consistent with this differentiation and dendritic cell survival. Many of the TNFR suggestion, treatment with RANKL/TRANCE was shown family receptors recruit various members of the TNF receptor- to enhance the function and survival of T cells and dendritic associated factor (TRAF) family for transduction of their signals cells [1,5]. In addition, RANKL/ODF has been demonstrated to NF-UB and c-Jun N-terminal kinase. In this study, the to cause the di¡erentiation of hematopoietic precursor cells involvement of TRAF family members and the activation of the into osteoclasts and to stimulate the bone resorbing activity JNK pathway in signal transduction by RANK were investi- of mature osteoclasts [4]. gated. TRAF1, 2, 3, 5, and 6 were found to bind RANK in vitro.
    [Show full text]